Product Information
QC PAIN RLF PM 25-500 MG GELTAB is a generic product labeled by Chain Drug Marketing Association, priced at $0.0439 per EA under NDC 83324016650. Its NADAC has been published 96 times since Dec 4, 2024.
Strength
500; 25 mg/1; mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324016650
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
7/31/2024
Pharmacological Classes
Price Statistics
The NADAC for QC PAIN RLF PM 25-500 MG GELTAB has been published 96 times since Dec 4, 2024, and over the history we have for it it has declined 20.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0439 per EA |
|---|---|
| All-time high | $0.0552 (Dec 11, 2024) |
| All-time low | $0.0436 (Feb 19, 2025) |
| 52-week high | $0.0470 |
| 52-week low | $0.0439 |
| Median price | $0.0464 |
| Average price | $0.0463 |
| Largest weekly change | -10.4% (Feb 19, 2025) |
| Weeks tracked | 96 |
| Tracking since | Dec 4, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Acetaminophen Diphenhydramine HCl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen Diphenhydramine HCl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC PAIN RLF PM 25-500 MG GELTAB?
The current National Average Drug Acquisition Cost (NADAC) for QC PAIN RLF PM 25-500 MG GELTAB, manufactured by Chain Drug Marketing Association, is $0.0439 per EA (NDC 83324016650), effective Sep 30, 2026.
How has the price of QC PAIN RLF PM 25-500 MG GELTAB changed over time?
Over the history we have for it, the NADAC for QC PAIN RLF PM 25-500 MG GELTAB has declined 20.4%. It has been tracked across 96 weekly CMS publications since Dec 4, 2024.
What are the highest and lowest recorded NADAC prices for QC PAIN RLF PM 25-500 MG GELTAB?
Since Dec 4, 2024, the NADAC for QC PAIN RLF PM 25-500 MG GELTAB has ranged from a low of $0.0436 (Feb 19, 2025) to a high of $0.0552 (Dec 11, 2024), with a median of $0.0464 per EA.
Are there cheaper alternatives to QC PAIN RLF PM 25-500 MG GELTAB?
No other NADAC-published product currently shares the active ingredient and strength of QC PAIN RLF PM 25-500 MG GELTAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QC PAIN RLF PM 25-500 MG GELTAB?
QC PAIN RLF PM 25-500 MG GELTAB (NDC 83324016650) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.